ACTH Deficiency Treatment Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

The ACTH Deficiency Treatment Market is Segmented by Drug Class (Glucocorticoids, Mineralocorticoids, and More), Formulation (Tablets and More, Route (Oral and More), Disease Etiology (Pituitary Adenoma/PitNET and More), Age Group (Neonates, Children, and More), Distribution (Hospital, and More), End User (Hospitals and More), and Geography (North America, Europe, Asia-Pacific, and More ). Market Forecasts are in Value (USD).

ACTH Deficiency Treatment Market Size and Share

ACTH Deficiency Treatment Market Size
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

ACTH Deficiency Treatment Market Analysis by Mordor Intelligence

The ACTH Deficiency Treatment Market size was valued at USD 0.79 billion in 2026 and is estimated to grow from USD 0.84 billion in 2027 to reach USD 1.17 billion by 2032, at a CAGR of 6.78% during the forecast period (2027-2032).

Central adrenal insufficiency remains underrecognized, leaving a sizable patient population outside routine testing and treatment. The broader use of immune checkpoint inhibitors and increased detection of pituitary tumors are expanding the treated patient base. Pediatric liquid formulations and modified-release hydrocortisone are influencing treatment decisions by improving dosing accuracy and cortisol coverage. However, supply continuity for emergency injectable products and evidence requirements for premium formulations continue to constrain adoption. The ACTH deficiency treatment market combines sustained demand for daily hormone replacement with a growing need for emergency care products and specialist follow-up.

Key Report Takeaways

  • By drug class, emergency corticosteroid therapy held 56.78% of the ACTH deficiency treatment market share in 2026, while glucocorticoids are projected to grow at a 9.12% CAGR through 2032.
  • By formulation, tablets held 45.67% of the ACTH deficiency treatment market share in 2026, while oral solution and suspension is projected to grow at an 8.99% CAGR through 2032.
  • By route of administration, the oral route accounted for 84.56% of the ACTH deficiency treatment market share in 2026, while intravenous hydrocortisone is projected to grow at an 8.76% CAGR through 2032.
  • By disease etiology, pituitary adenoma or PitNET held 43.56% of the ACTH deficiency treatment market share in 2026, while post-pituitary surgery is projected to grow at a 7.56% CAGR through 2032.
  • By patient age group, adults held 71.22% of the ACTH deficiency treatment market share in 2026, while neonates and Infants are projected to grow at a 9.55% CAGR through 2032.
  • By distribution channel, hospital pharmacies held 48.67% of the ACTH deficiency treatment market share in 2026, while online pharmacies are projected to grow at an 8.34% CAGR through 2032.
  • By end user, hospitals held 52.33% of the ACTH deficiency treatment market share in 2026, while specialty endocrinology clinics are projected to grow at a 7.52% CAGR through 2032.
  • By geography, North America held 39.65% of the ACTH deficiency treatment market share in 2026, while Asia-Pacific is projected to grow at a 10.45% CAGR through 2032.

Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.

ACTH Deficiency Treatment Market Segment Analysis

By Drug Class:

Emergency Corticosteroid Therapy Leads While Glucocorticoids Grows Faster

Emergency Corticosteroid Therapy held 56.78% of the ACTH deficiency treatment market share in 2026. Healthcare providers prescribe emergency kits for diagnosed patients, including those without a prior crisis. Sodium succinate remains the primary injectable product, while the UK withdrawal of sodium phosphate has influenced prescribing patterns. The market relies on both maintenance replacement and acute intervention therapies.

Glucocorticoids are projected to grow at a CAGR of 9.12% through 2032. Modified-release products and adjunct therapies are expanding treatment options beyond standard replacement. Providers consider clinical convenience, treatment precision, supply reliability, and reimbursement when selecting products. Generic options remain important where affordability determines access.

Need more granular breakdown of segment shares?

Get tailored market insights for your requirements.

ACTH Deficiency Treatment Market Share by Drug Class, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
ACTH Deficiency Treatment Market Share by Drug Class, 2026

By Formulation:

Tablets Leads While Oral Solution and Suspension Grows Faster

Tablets held 45.67% of the ACTH deficiency treatment market share in 2026. They remain widely accessible across major markets and support standard daily replacement regimens. Liquid formulations enable more precise dosing for young children. KHINDIVI’s approval and proposed expansion into the under-5 population support this shift.

Oral Solutions and Suspensions are projected to grow at a CAGR of 8.99% through 2032. Demand is supported by the need for flexible pediatric dosing and improved treatment precision. Providers also consider supply reliability, clinical convenience, and reimbursement in product selection. Generic options remain relevant in price-sensitive markets.

By Route of Administration:

Oral Route Leads While Intravenous Hydrocortisone Grows Faster

Oral administration held 84.56% of the ACTH deficiency treatment market share in 2026. Oral products support daily, lifelong replacement therapy and generate predictable prescription volumes. Intramuscular products remain important for emergency kits. Intravenous use is increasing with pituitary surgery and immune checkpoint inhibitor-related crises.

Intravenous Hydrocortisone is projected to grow at a CAGR of 8.76% through 2032. Growth is supported by its role in acute care and hospital-based treatment settings. Providers prioritize treatment precision, product availability, and reimbursement considerations. Generic products continue to support access where affordability is a key factor.

Segment this market the way your business does.

Get tailored market insights for your requirements.

ACTH Deficiency Treatment Market Share by Route of Administration, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
ACTH Deficiency Treatment Market Share by Route of Administration, 2026

By Disease Etiology:

Pituitary Adenoma or PitNET Leads While Post-Pituitary Surgery Grows Faster

Pituitary Adenoma or PitNET held 43.56% of the ACTH deficiency treatment market share in 2026. Pituitary tumors create a stable patient population requiring long-term cortisol replacement. A 2025 study reported ACTH deficiency in 36% of patients before surgery and 42% at three months after surgery. Routine postoperative endocrine assessments improve patient identification.

Post-Pituitary Surgery is projected to grow at a CAGR of 7.56% through 2032. Growth is driven by increased surgical interventions and routine endocrine monitoring after surgery. Providers evaluate treatment options based on clinical needs, supply reliability, and reimbursement. Generic therapies remain important for improving affordability and access.

By Patient Age Group:

Adults Leads While Neonates and Infants Grows Faster

Adults held 71.22% of the ACTH deficiency treatment market share in 2026. This group generates the largest ongoing prescription demand due to the prevalence of pituitary disease and treatment-related causes. Newborn screening and specialist neonatal care support earlier identification of congenital cases. Pediatric liquid formulations reduce reliance on compounded suspensions.

Neonates and Infants are projected to grow at a CAGR of 9.55% through 2032. Growth is supported by earlier diagnosis and the availability of age-appropriate liquid formulations. Providers prioritize dosing precision, ease of administration, and product availability. Generic options remain important where affordability affects treatment access.

Need more granular breakdown of segment shares?

Get tailored market insights for your requirements.

ACTH Deficiency Treatment Market Share by Patient Age Group, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
ACTH Deficiency Treatment Market Share by Patient Age Group, 2026

By Distribution Channel:

Hospital Pharmacies Leads While Online Pharmacies Grows Faster

Hospital Pharmacies held 48.67% of the ACTH deficiency treatment market share in 2026. Hospitals dispense initial therapy after crises, pituitary surgery, and oncology-related endocrine evaluations. Retail pharmacies support chronic maintenance prescriptions. Specialty home delivery supports refills, adherence monitoring, and clinical services for rare-disease therapies.

Online Pharmacies are projected to grow at a CAGR of 8.34% through 2032. Growth is supported by demand for convenient refill services and improved access to maintenance therapies. Providers consider supply reliability, reimbursement, and patient support capabilities. Generic options remain important in affordability-driven markets.

By End User:

Hospitals Leads While Specialty Endocrinology Clinics Grows Faster

Hospitals held 52.33% of the ACTH deficiency treatment market share in 2026. Hospitals manage diagnosis, acute stabilization, surgery, and initial emergency-kit prescriptions. Specialty endocrinology clinics increasingly manage stable patients after discharge. Regular ACTH and cortisol monitoring supports structured outpatient follow-up.

Specialty Endocrinology Clinics are projected to grow at a CAGR of 7.52% through 2032. Growth is supported by the increasing transition of stable patients to outpatient care. Providers focus on treatment precision, follow-up monitoring, and reimbursement considerations. Generic therapies remain important for expanding patient access.

Segment this market the way your business does.

Get tailored market insights for your requirements.

ACTH Deficiency Treatment Market Share by End User, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
ACTH Deficiency Treatment Market Share by End User, 2026

Geography Analysis

North America

North America held 39.65% of the ACTH deficiency treatment market share in 2026, supported by specialist endocrinology services, pituitary centers, and established specialty pharmacy networks. The FDA approved KHINDIVI in May 2025 for eligible pediatric patients. Increasing checkpoint inhibitor use is also driving endocrinology referrals. Canada contributes through provincial drug coverage, while Mexico remains reliant on generic hydrocortisone due to uneven access to specialist care and precision formulations.

Asia-Pacific

Asia-Pacific is projected to grow at a 10.45% CAGR through 2032, the highest regional rate in the ACTH deficiency treatment market. Japan broadly reimburses hydrocortisone replacement and has a growing checkpoint inhibitor-related patient population. China is expanding rare-disease and pituitary care capacity in major hospitals, while improved MRI access is increasing the identification of post-surgical cases. India and Southeast Asia offer long-term growth potential but remain constrained by generic reliance and limited specialist density outside major cities.

Western Europe has established pituitary networks and is adopting modified-release hydrocortisone. The European Commission and UK MHRA expanded Efmody’s adrenal insufficiency indication in April and May 2026. Supply disruptions in the United Kingdom have increased focus on injectable supply resilience and autoinjector development. GCC countries, South Africa, Brazil, and Argentina face latent demand, as clinical awareness, testing capacity, and specialist access remain uneven.

ACTH Deficiency Treatment Market Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Market Concentration

ACTH Deficiency Treatment Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

The ACTH deficiency treatment market is moderately fragmented. Generic manufacturers, including Amneal, Aurobindo, Cipla, Dr. Reddy’s Laboratories, Lupin, Sandoz, Sun Pharma, Teva, Viatris, and Zydus Lifesciences, compete across oral tablets and standard injectables. Their market position depends on pricing, active ingredient sourcing, and supply reliability. Pfizer’s Solu-Cortef, Fresenius Kabi, and Hikma maintain a presence in hospital emergency injectable care.

Specialty companies compete through differentiated formulations, regulatory protection, and clinical evidence. Eton introduced KHINDIVI and submitted its pediatric label expansion request in July 2026. Immedica expanded Efmody into adrenal insufficiency in the EU and UK during 2026. Neurocrine’s crinecerfont data showed sustained glucocorticoid dose reductions in adults with classic congenital adrenal hyperplasia. These initiatives support premium positioning where payers recognize additional clinical value.

An emergency hydrocortisone autoinjector remains a key market opportunity. CROSSJECT and Eton are advancing the ZENEO program, while Amphastar licensed AMP-110 in January 2026. Diagnostic partnerships with oncology centers may also enable earlier patient engagement across the treatment pathway. Orphan designations and formulation patents can extend exclusivity beyond commodity replacement products, while the market remains fragmented as no company controls both chronic replacement and emergency treatment.

ACTH Deficiency Treatment Industry Leaders

  1. Pfizer Inc.

  2. Teva Pharmaceutical Industries Ltd

  3. Viatris Inc.

  4. Hikma Pharmaceuticals PLC

  5. Sandoz Group AG

  6. *Disclaimer: Major Players sorted in no particular order

ACTH Deficiency Treatment Market Companies Covered in this Report

  • Amneal Pharmaceuticals
  • Amphastar Pharmaceuticals
  • Aurobindo Pharma
  • Cipla
  • Crinetics Pharmaceuticals, Inc.
  • Dr. Reddy’s Laboratories
  • Eton Pharmaceuticals, Inc.
  • Fresenius
  • H. Lundbeck
  • Hikma Pharmaceuticals
  • Immedica Pharma AB
  • Lupin
  • Neurocrine Biosciences
  • Novitium Pharma LLC
  • Pfizer
  • Sandoz Group AG
  • Sun Pharmaceuticals Industries
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Viatris
  • Zydus Lifesciences Limited

Recent Industry Developments in ACTH Deficiency Treatment Market

  • May 2026: Immedica Pharma received MHRA approval for Efmody for adolescents aged 12 and older and adults with adrenal insufficiency.
  • April 2026: The European Commission extended Efmody’s indication to adolescents aged 12 and older and adults with adrenal insufficiency.
  • January 2026: Amphastar licensed AMP-110, a fully synthetic human ACTH analog, for commercialization in the United States and Canada.
  • July 2025: Neurocrine presented one-year CAHtalyst Adult data showing mean glucocorticoid dose reductions of 25% and 30% in the continuous and crossover CRENESSITY groups, respectively.

Table of Contents for ACTH Deficiency Treatment Industry Report

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET LANDSCAPE

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Recognition of Secondary and Tertiary Adrenal Insufficiency
    • 4.2.2 Expansion of Pediatric Precision-Dosing Formulations
    • 4.2.3 Adoption of Circadian-Profile Hydrocortisone Formulations
    • 4.2.4 Growth in Emergency Adrenal-Crisis Preparedness
    • 4.2.5 Increasing Diagnosis After Pituitary and Immune-Checkpoint Disorders
    • 4.2.6 ACTH-Sparing and Glucocorticoid-Sparing Innovation in Congenital Adrenal Hyperplasia
  • 4.3 Market Restraints
    • 4.3.1 Long-Term Over-Replacement Toxicity and Monitoring Burden
    • 4.3.2 Hydrocortisone Injection Supply Interruptions
    • 4.3.3 Limited Clinical Evidence for Hard-Endpoint Benefits of Modified-Release Therapy
    • 4.3.4 Fragmented Diagnosis and Under-Recognition of Central Adrenal Insufficiency
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Competitive Rivalry
    • 4.7.2 Threat of New Entrants
    • 4.7.3 Bargaining Power of Suppliers
    • 4.7.4 Bargaining Power of Buyers
    • 4.7.5 Threat of Substitutes

5. MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

  • 5.1 By Drug Class
    • 5.1.1 Glucocorticoids
    • 5.1.2 Mineralocorticoids
    • 5.1.3 Emergency Corticosteroid Therapy
    • 5.1.3.1 Hydrocortisone Sodium Succinate
    • 5.1.3.2 Hydrocortisone Sodium Phosphate
    • 5.1.3.3 Injectable Dexamethasone
    • 5.1.4 Other Drug Classes
  • 5.2 By Formulation
    • 5.2.1 Tablets
    • 5.2.2 Injectables
    • 5.2.3 Oral Solution and Suspension
  • 5.3 By Route of Administration
    • 5.3.1 Oral
    • 5.3.2 Intravenous
    • 5.3.3 Intramuscular
  • 5.4 By Disease Etiology
    • 5.4.1 Pituitary Adenoma or Pituitary Neuroendocrine Tumor
    • 5.4.2 Hypothalamic Disorder
    • 5.4.3 Post-Pituitary Surgery
    • 5.4.4 Radiation Induced ACTH Deficiency
    • 5.4.5 Traumatic Brain Injury Associated ACTH Deficiency
    • 5.4.6 Other Disease Etiology
  • 5.5 By Patient Age Group
    • 5.5.1 Neonates and Infants
    • 5.5.2 Children
    • 5.5.3 Adolescents
    • 5.5.4 Adults
    • 5.5.5 Older Adults
  • 5.6 By Distribution Channel
    • 5.6.1 Hospital Pharmacies
    • 5.6.2 Retail Pharmacies
    • 5.6.3 Online Pharmacies
    • 5.6.4 Other Distribution Channels
  • 5.7 By End User
    • 5.7.1 Hospitals
    • 5.7.2 Specialty Endocrinology Clinics
    • 5.7.3 Diagnostic Laboratories
    • 5.7.4 Home-Care and Self-Management
    • 5.7.5 Other End Users
  • 5.8 By Geography
    • 5.8.1 North America
    • 5.8.1.1 United States
    • 5.8.1.2 Canada
    • 5.8.1.3 Mexico
    • 5.8.2 Europe
    • 5.8.2.1 Germany
    • 5.8.2.2 United Kingdom
    • 5.8.2.3 France
    • 5.8.2.4 Italy
    • 5.8.2.5 Spain
    • 5.8.2.6 Rest of Europe
    • 5.8.3 Asia-Pacific
    • 5.8.3.1 China
    • 5.8.3.2 India
    • 5.8.3.3 Japan
    • 5.8.3.4 Australia
    • 5.8.3.5 South Korea
    • 5.8.3.6 Rest of Asia-Pacific
    • 5.8.4 Middle East and Africa
    • 5.8.4.1 GCC
    • 5.8.4.2 South Africa
    • 5.8.4.3 Rest of Middle East and Africa
    • 5.8.5 South America
    • 5.8.5.1 Brazil
    • 5.8.5.2 Argentina
    • 5.8.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
    • 6.3.1 Amneal Pharmaceuticals, Inc.
    • 6.3.2 Amphastar Pharmaceuticals, Inc.
    • 6.3.3 Aurobindo Pharma Limited
    • 6.3.4 Cipla Limited
    • 6.3.5 Crinetics Pharmaceuticals, Inc.
    • 6.3.6 Dr. Reddy's Laboratories Limited
    • 6.3.7 Eton Pharmaceuticals, Inc.
    • 6.3.8 Fresenius Kabi AG
    • 6.3.9 H. Lundbeck A/S
    • 6.3.10 Hikma Pharmaceuticals PLC
    • 6.3.11 Immedica Pharma AB
    • 6.3.12 Lupin Limited
    • 6.3.13 Neurocrine Biosciences, Inc.
    • 6.3.14 Novitium Pharma LLC
    • 6.3.15 Pfizer Inc.
    • 6.3.16 Sandoz Group AG
    • 6.3.17 Sun Pharmaceutical Industries Limited
    • 6.3.18 Takeda Pharmaceuticals Inc.
    • 6.3.19 Teva Pharmaceutical Industries Ltd
    • 6.3.20 Viatris Inc.
    • 6.3.21 Zydus Lifesciences Limited

7. MARKET OPPORTUNITIES AND FUTURE OUTLOOK

  • 7.1 White-Space and Unmet-Need Assessment

Global ACTH Deficiency Treatment Market Report Scope

As per the scope of the report, adrenocorticotropic hormone (ACTH) deficiency is an endocrine disorder characterized by inadequate production or secretion of ACTH by the anterior pituitary gland, resulting in insufficient stimulation of the adrenal cortex and reduced production of cortisol. ACTH plays a critical role in regulating the body's stress response, metabolism, blood pressure, and inflammatory processes through its influence on adrenal hormone secretion.

The ACTH deficiency treatment market is segmented by drug class, formulation, route of administration, disease etiology, patient age group, distribution channel, end user, and geography. By drug class, the market includes glucocorticoids, mineralocorticoids, emergency corticosteroid therapy, hydrocortisone sodium succinate, hydrocortisone sodium phosphate, injectable dexamethasone, and other drug classes. By formulation, the market is segmented into tablets, injectables, and oral solutions and suspensions. By route of administration, the market is categorized into oral, intravenous, and intramuscular administration. By disease etiology, the market is segmented into pituitary adenoma or pituitary neuroendocrine tumor, hypothalamic disorders, post-pituitary surgery, radiation-induced ACTH deficiency, traumatic brain injury-associated ACTH deficiency, and other disease etiologies. By patient age group, the market includes neonates and infants, children, adolescents, adults, and older adults. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels. By end user, the market is categorized into hospitals, specialty endocrinology clinics, diagnostic laboratories, home care and self-management, and other end users. By geography, the market is analyzed across North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers market sizes and forecasts in terms of value (USD) for the above segments.

Segmentation Overview

By Drug Class
ACTH Deficiency Treatment Market segmentation breakdown
Glucocorticoids
Mineralocorticoids
Emergency Corticosteroid Therapy Hydrocortisone Sodium Succinate
Hydrocortisone Sodium Phosphate
Injectable Dexamethasone
Other Drug Classes
By Formulation
ACTH Deficiency Treatment Market segmentation breakdown
Tablets
Injectables
Oral Solution and Suspension
By Route of Administration
ACTH Deficiency Treatment Market segmentation breakdown
Oral
Intravenous
Intramuscular
By Disease Etiology
ACTH Deficiency Treatment Market segmentation breakdown
Pituitary Adenoma or Pituitary Neuroendocrine Tumor
Hypothalamic Disorder
Post-Pituitary Surgery
Radiation Induced ACTH Deficiency
Traumatic Brain Injury Associated ACTH Deficiency
Other Disease Etiology
By Patient Age Group
ACTH Deficiency Treatment Market segmentation breakdown
Neonates and Infants
Children
Adolescents
Adults
Older Adults
By Distribution Channel
ACTH Deficiency Treatment Market segmentation breakdown
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
By End User
ACTH Deficiency Treatment Market segmentation breakdown
Hospitals
Specialty Endocrinology Clinics
Diagnostic Laboratories
Home-Care and Self-Management
Other End Users
By Geography
ACTH Deficiency Treatment Market segmentation breakdown
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
India
Japan
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
ACTH Deficiency Treatment Market segmentation breakdown
By Drug Class Glucocorticoids
Mineralocorticoids
Emergency Corticosteroid Therapy Hydrocortisone Sodium Succinate
Hydrocortisone Sodium Phosphate
Injectable Dexamethasone
Other Drug Classes
By Formulation Tablets
Injectables
Oral Solution and Suspension
By Route of Administration Oral
Intravenous
Intramuscular
By Disease Etiology Pituitary Adenoma or Pituitary Neuroendocrine Tumor
Hypothalamic Disorder
Post-Pituitary Surgery
Radiation Induced ACTH Deficiency
Traumatic Brain Injury Associated ACTH Deficiency
Other Disease Etiology
By Patient Age Group Neonates and Infants
Children
Adolescents
Adults
Older Adults
By Distribution Channel Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
By End User Hospitals
Specialty Endocrinology Clinics
Diagnostic Laboratories
Home-Care and Self-Management
Other End Users
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
India
Japan
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America

Key Questions Answered in the Report

What is driving demand for ACTH deficiency treatment?

Growing recognition of central adrenal insufficiency, oncology-related cases, and pituitary surgery are expanding treatment need.

What is the projected growth rate through 2032?

The ACTH deficiency treatment market is projected to grow at a 6.78% CAGR from 2027 to 2032.

Which treatment class holds the largest share?

Emergency Corticosteroid Therapy held 56.78% in 2026.

Which patient group is growing fastest?

Neonates and Infants are projected to grow at a 9.55% CAGR through 2032.

Which region is growing fastest?

Asia-Pacific is projected to grow at a 10.45% CAGR through 2032.

Is the competitive environment concentrated?

The market concentration score is 4 out of 10 because many generic and specialty companies compete across different products, with no disclosed top-player share supporting a concentrated structure.

Page last updated on: